U.S. Specialized REITs Stock News

If you are wondering whether Chemed at around US$374 per share still reflects its underlying worth, the current valuation picture offers some clear signals to work through. The share price has pulled back recently, with a 2.4% decline over the past week, a 21.8% drop over the last 30 days, and a 38.3% decline over the past year. This may have shifted how investors see both risk and potential reward. Recent coverage has focused on Chemed's role in healthcare services and how sector wide...

At its March 24, 2025 AGM, Coca-Cola FEMSA, S.A.B. de C.V. approved a cash dividend of MXN 0.9675 per share (MXN 7.74 per KOF UBL unit) for fiscal 2025, to be paid in four equal installments during April, July, October, and December 2026. This multi‑installment dividend, spreading payments across the year, gives investors greater visibility on expected cash returns and may influence how they assess the company’s capital allocation and income profile. We’ll now examine how this AGM-approved,...

Earlier this week, PPG Industries introduced PPG InsightsNav, a global analytics platform that helps marine customers standardize and analyze seastock coatings purchasing data, while also reaffirming a commitment to invest US$10.00 million through 2030 in skilled trades programs tied to advanced manufacturing and coatings applications. Together, the digital InsightsNav offering and long-term skilled trades funding highlight how PPG is pairing data-driven tools with workforce development to...

Earlier this month, Cheniere Energy closed a private offering of US$1.00 billion of 5.200% Senior Notes due 2036 and US$750.00 million of 6.000% Senior Notes due 2056, issued just below par under an indenture with The Bank of New York Mellon and carrying customary covenants and optional redemption features. The unregistered Rule 144A and Regulation S issuance adds long-dated, senior unsecured debt that Cheniere can later exchange into registered securities, potentially broadening its...

HP (NYSE:HPQ) has introduced HP NearSense, a new cross-device experience built with Google and Qualcomm for secure workflows across HP PCs, Android devices, and multiple workspaces. The company is expanding its local AI layer, HP IQ, across devices to support on-device, context-aware productivity features. HP also announced TPM Guard hardware to counter advanced physical attacks on business PCs and quantum-resistant security for its printer portfolio. For investors tracking NYSE:HPQ, these...

Earlier this month, SentinelOne announced it is expanding its partnership with Cloudflare to feed Cloudflare’s Zero Trust and edge security telemetry directly into SentinelOne’s Singularity AI SIEM, creating a unified, AI-driven threat detection and response experience for joint enterprise customers. This deeper integration positions Cloudflare’s network and security data as a core ingredient in AI-powered security operations, potentially enhancing its relevance in the shift toward...

On March 18, 2026, ScottsMiracle-Gro, Bonnie Plants and Gardenuity launched the Inspired to Gro Patio Garden Collection, bundling plant nutrients, rooted starter plants and guided digital support into a single patio-gardening product now sold on Amazon, Bonnieplants.com and Gardenuity.com. The collaboration stands out by pairing physical gardening inputs with Gardenuity’s personalized coaching and weather-based alerts, aiming to remove common barriers that keep new gardeners from starting...

Ocugen (OCGN) has attracted fresh attention after recent trading left the shares at US$1.95, against a market value of about US$648.8m. This has prompted investors to reassess how its pipeline and financials line up. See our latest analysis for Ocugen. Recent trading has been choppy, with a 1-day share price return of 1.56% set against a 7-day share price return decline of 14.85%. However, the 90-day share price return of 35.42% and 1-year total shareholder return of 163.87% point to momentum...

Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock. The share price return sits at 2.2% over 7 days, 6.5% over 30 days, 73.5% year to date and 70.1% over the last year, alongside a 64.0% decline over 3 years and a 59.1% decline over 5 years. Recent headlines around Moderna have focused on its position in the pharmaceutical and biotech space and how investors are reassessing companies in this part of the...

In March 2026, Uranium Energy Corp. reported state approvals and startup of three new header houses at Christensen Ranch in Wyoming, alongside an NRC docket for its planned U.S. uranium conversion facility, advancing both production capacity and licensing progress for refining and conversion. These steps move the company closer to its goal of becoming a fully vertically integrated American nuclear fuel supplier, potentially enhancing control over the domestic fuel chain and mitigating...

Event driven move in Paymentus Holdings (PAY) Paymentus Holdings (PAY) is back on investor radars after recent trading activity highlighted a mixed return profile, with gains over the past month set against a roughly 21% decline over the past 3 months. See our latest analysis for Paymentus Holdings. At a share price of US$25.10, Paymentus sits between a modest 30 day share price return and a much weaker 90 day share price return, while the 3 year total shareholder return above 100% points to...

Investor activism meets softer quarterly results AutoNation (AN) is facing closer investor scrutiny after a softer Q4, with revenue down 3.9% year on year and earnings missing analyst estimates, even as After-Sales and Customer Financial Services reported record gross profit. See our latest analysis for AutoNation. AutoNation's share price has softened recently, with a 30 day share price return of 1.64% decline and a 90 day share price return of 8.82% decline, even as the 1 year total...

Wondering if Oncolytics Biotech at around US$0.95 is offering value or just extra risk? This article breaks down what that price tag could really mean for you. The stock is roughly flat year to date with a 3.4% decline. It has returned 54.7% over the last year, which can raise questions about how much potential or risk might already be reflected in the price. Recent coverage has focused on Oncolytics Biotech's progress as a clinical stage cancer therapy developer and the implications of its...

Valero Energy (NYSE:VLO) is facing a worker lawsuit that alleges negligence after the recent explosion at its Port Arthur refinery. The suit claims gross negligence related to safety practices and working conditions at one of Valero's largest facilities. This legal action adds fresh scrutiny to the company's operational risk management and potential liability exposure. Valero is one of the largest independent refiners in the US, with operations that supply transportation fuels and other...

IDEAYA Biosciences recently updated investors on the timing of topline data from its Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma, indicating that the database lock occurred in the first half of April and that a live webcast will follow to discuss the results. This combination of a clarified data-readout timeline and a planned investor-and-expert webcast highlights how the trial’s outcome could meaningfully shape perceptions of IDEAYA’s clinical...

Maze Therapeutics reported promising Phase II results for its APOL1-mediated kidney disease candidate MZE829. The company plans to move MZE829 into pivotal testing, targeting the same indication as Vertex Pharmaceuticals' inaxaplin program. This development introduces a new competitor to NasdaqGS:VRTX in the APOL1-mediated kidney disease space. Vertex Pharmaceuticals, listed as NasdaqGS:VRTX, is known for its focus on serious diseases with high unmet need, and inaxaplin is one of its key...

Worthington Enterprises (WOR) has reported a busy quarter, with Q3 2026 revenue at US$378.7 million and basic EPS of US$0.93, alongside trailing 12 month EPS of US$2.27 that sits against reported earnings growth of 84.3% over the past year and a longer term 5 year earnings decline of 47.8% per year. Over recent quarters the company has seen revenue move from US$274.0 million in Q2 2025 to US$304.5 million in Q3 2025 and then to US$378.7 million in Q3 2026. Quarterly basic EPS shifted from...

Cipher Digital (CIFR) has been drawing attention after its recent rebrand from Cipher Mining Inc., shifting the focus toward a broader digital infrastructure story that is built around bitcoin mining and high performance compute hosting in the United States. See our latest analysis for Cipher Digital. The recent rebrand comes as Cipher Digital’s share price sits at US$15.88, with short term momentum reflected in a 1-day share price return of 6.72% and a 1-year total shareholder return that is...

Core & Main (CNM) drew investor attention after its latest quarterly report, which paired a 16th consecutive year of sales growth with a cautious 2% to 3% net sales outlook for fiscal 2026. See our latest analysis for Core & Main. The cautious 2% to 3% net sales outlook has weighed on sentiment in the short term, with the 30 day share price return of 7.43% and 90 day share price return of 6.68% pointing to cooling momentum despite a 3 year total shareholder return of 124.76%. If Core & Main’s...

If you are wondering whether BioCryst Pharmaceuticals at US$9.40 still offers value, it helps to start by lining up the recent share performance with what the fundamentals suggest the stock might be worth. Over the short term, the share price return sits at 2.6% over 7 days, 24.0% over 30 days and 25.3% year to date, with a 20.5% return over 1 year and 9.8% over 3 years, compared with a 5 year return of a 7.6% decline. These moves are occurring as investors continue to respond to ongoing...

Over the last 7 days, the United States market has remained flat, yet it has risen by 16% over the past year with expectations of earnings growing annually by a similar rate in the coming years. In this context of steady growth, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and potential to outperform these promising market conditions.

In the last week, the United States market has stayed flat, although it is up 16% over the past year with earnings forecasted to grow by 16% annually. In this environment, identifying stocks trading below their estimated intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.

If you are wondering whether Pitney Bowes at around US$10.91 is still offering value or if the easy part of the move is behind it, the starting point is understanding how its current price lines up with different valuation checks. The stock has posted returns of 11.3% over the last 7 days, 5.1% over the past month, 5.6% year to date and 18.6% over the last year, while the 3 year return is very large and the 5 year return sits at 61.5%. Recent headlines have focused on Pitney Bowes in the...

Coca-Cola (KO) is committing up to US$650 million to expand its Fairlife facility in Michigan, adding 245,000 square feet of production space and 150 jobs, a meaningful operational development for long term shareholders. See our latest analysis for Coca-Cola. Coca-Cola shares trade at US$75.25 after a 7.33% 90 day share price return and 8.87% year to date share price return. The 5 year total shareholder return of 65.70% points to steady long term compounding, suggesting recent momentum has...